Tariffs and Trade Impact - President Trump announced an additional 100% tariff on Chinese goods, raising the total tariff burden on Chinese imports to 130% [2] - Following this announcement, the S&P 500 dropped 2.7%, the Dow Jones Industrial Average fell 878 points (1.9%), and the Nasdaq Composite decreased by 3.6% [3] - Boeing shares fell 4.1% after threats of a parts export ban, highlighting the negative impact of geopolitical tensions on stock performance [4] Pharmaceutical Sector Developments - A major deal was announced to reduce prices of GLP-1 weight-loss drugs, with prices for Ozempic and Wegovy expected to drop from $1,000-$1,350 to $350, and as low as $245 for Medicare and Medicaid beneficiaries [6] - Despite the price cuts, shares of Novo Nordisk and Eli Lilly fell by 3% and 3% respectively, indicating market skepticism about the long-term benefits of price reductions [7] - Earlier, Indian generic drugmakers saw stock surges due to potential exemptions from new import tariffs, contrasting the mixed reactions to price cuts [9] Geopolitical and Economic Agreements - President Trump announced a $100 billion trade deal with Uzbekistan, which includes investments in critical minerals and aviation, although analysts question the long-term viability of such unilateral agreements [11] - The U.S. Supreme Court is reviewing the legality of recent tariff actions, with a ruling expected by early 2026 that could impact market stability [5] Meatpacking Industry Scrutiny - An antitrust investigation was launched into major meatpacking companies, causing shares of JBS NV to drop by 6.2% in after-hours trading [12][13] - The investigation is viewed skeptically by agricultural economists, who suggest it may not lead to lower consumer prices and could disrupt market efficiency [13]